

1 **Vaccine hesitancy and non-vaccination in an Irish paediatric outpatient population**

2

3 Whelan SO<sup>a\*</sup>, Moriarty F<sup>b</sup>, Lawlor L<sup>a</sup>, Gorman K<sup>c</sup>, d, Beamish, J<sup>a</sup>

4

5 <sup>a</sup>Department of General Paediatrics, CHI at Temple Street, Dublin, Ireland.

6 <sup>b</sup>School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland,

7 Dublin, Ireland.

8 <sup>c</sup>Department of Neurology and Clinical Neurophysiology, CHI at Temple Street, Dublin,

9 Ireland.

10 <sup>d</sup>School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland.

11 \* Corresponding author – [s.whelan@rocketmail.com](mailto:s.whelan@rocketmail.com);

12 *Current address: Department of Paediatrics, Cork University Hospital, Cork, Ireland. .*

13

14 **Contributorship Statement:**

15 SOW conceived the study. SOW and JB designed the study. SOW and LL collected the data.

16 FM conducted the analysis. All authors interpreted the findings. SOW, FM and KG drafted

17 the manuscript. All authors critically revised and approved the final manuscript. JB oversaw

18 the study process.

19

20

21

22

23

24

25 **Abstract**

26

27 *Objective:* To administer the Parent Attitudes Childhood Vaccines (PACV) questionnaire to  
28 assess vaccine hesitancy and its relationship with non-vaccination.

29

30 *Design:* A cross-sectional study using the 15-item PACV questionnaire, with  
31 sociodemographic questions.

32

33 *Setting:* Outpatient department in a tertiary paediatric hospital, Dublin, Ireland.

34

35 *Participants:* Parents/caregivers of children attending general paediatric clinics.

36

37 *Main outcome measures:* PACV score and reported non-vaccination. We assessed  
38 sociodemographic factors associated with PACV score and accuracy of the PACV in  
39 predicting non-vaccination.

40

41 *Results:* In total, 436 participants completed the questionnaire. 5.5% of our population  
42 reported non-vaccination. HPV and MMR vaccines were the most commonly cited vaccines  
43 of concern (11.5% and 6.7% respectively) and autism spectrum disorder was the most  
44 commonly side effect of concern (4.3%). Mean PACV score was 26.9 (SD 19.1), with a  
45 significant difference between non-vaccinators and vaccinators (53.2 vs 25.3,  $p < 0.001$ ).  
46 Safety and efficacy concerns were the major contributor to non-vaccination. 14.4% of our  
47 population were vaccine-hesitant using the conventional cut-off score, which increased to  
48 22% when using an optimal cut-off which maximised sensitivity and specificity. The accuracy

49 of the PACV score to identify non-vaccination was good (area under the ROC curve = 0.827)

50 and the optimal cut-off had a high negative predictive value (98.5%).

51

52 *Conclusions:* PACV identified non-vaccination with high accuracy in our population. It may

53 be useful to screen vaccine hesitant parents who could benefit from interventions to

54 improve uptake.

55

56 Keywords: vaccine hesitancy, vaccine refusal, childhood vaccinations, vaccine promotion,

57 public health, immunisation

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72 **Funding Sources**

73

74 This research did not receive any specific grant from funding agencies in the public,

75 commercial, or not-for-profit sectors.

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120 **Introduction**

121

122 Vaccination is amongst the most successful public health interventions, second only to the  
123 provision of clean drinking water in reducing the burden of infectious diseases [1]. Globally,  
124 child mortality from vaccine-preventable diseases has fallen by more than two-thirds in the  
125 last three decades, in large part due to the increased availability of vaccinations [2]. While  
126 this benefit is preferentially seen in the developing world, it is estimated that childhood  
127 vaccination of a single year birth cohort in the United States of America (USA) prevented  
128 42,000 deaths, and 20 million disease cases [3]. This does not include the deaths from  
129 Human Papilloma Virus (HPV)-related cancers which will ultimately result from the  
130 introduction of HPV vaccination [4].

131

132 Despite these successes, public confidence in vaccination has fallen worldwide, with  
133 associated reductions in vaccination rates in the United Kingdom (UK) and Ireland [5,6],  
134 resulting in disease outbreaks [7,8]. Even modest falls in vaccine uptake have significant  
135 public health and economic consequences, with one model suggesting a 5% reduction in  
136 measles, mumps rubella (MMR) uptake is associated with a 3-fold annual increase in cases  
137 [9]. This drop in uptake is multifactorial, but chief among the causes is vaccine hesitancy,  
138 recognised by the World Health Organisation (WHO) in 2019 as one of biggest threats to  
139 global health [10].

140

141 There are variations in how vaccine hesitancy is defined. The WHO's Strategic Advisory  
142 Group of Experts on Immunization (SAGE) Working Group defines it as '*as a delay in*  
143 *acceptance, or refusal of vaccines, despite their availability*' [11]. Other groups have created

144 alternative models of vaccine behaviour, several of which divide the population into  
145 categories depending on attitudes and responses to vaccination. The common thread  
146 through these theories is the concept that a population's attitudes towards vaccination  
147 exists on a continuum between demand for all vaccines on the one hand, and rejection of all  
148 on the other. The cohort between the extremes are 'vaccine hesitant'. Determinants of  
149 vaccine hesitancy have been summarised using the WHO's 3 Cs model – confidence in the  
150 vaccines and the system that administers them, complacency regarding the risks of vaccine  
151 preventable diseases, and convenience of physically getting the vaccination. These are all  
152 subject to contextual, individual or vaccine specific influences [11].

153

154 This is a complex and context specific group, with a wide variety of views which are time,  
155 geography and vaccine dependent. Parents may choose to accept some childhood vaccines  
156 completely, delay or decline doses of some, and decline others outright. They may make  
157 different choices for different doses and different children, as their view changes over time.  
158 Local factors, such as outbreaks of vaccine preventable diseases may also encourage  
159 vaccination, while locally reported vaccine side effect fears may have the opposite effect. In  
160 addition, vaccine hesitancy cannot be solely based on vaccine uptake, as it is possible for  
161 vaccines to be accepted, while still holding concerns regarding this choice. Given this  
162 heterogeneity, it is perhaps unsurprising that the label of vaccine hesitancy is variably  
163 applied in different studies, impacting the comparability of results between studies [12,13].

164

165 For paediatricians and all healthcare professionals, understanding, targeting and influencing  
166 vaccine-hesitant cohorts towards positive vaccination choices is an important but  
167 challenging role. While consistently rated as one of the most trusted sources of information

168 on vaccines [14], physicians frequently report feeling unprepared for dealing with vaccine  
169 hesitancy.

170

171 While clearly a population who need attention from healthcare professionals, identifying  
172 vaccine-hesitant parents is challenging. A recent systematic review noted there have been  
173 no experimental studies of interventions to enhance vaccine uptake in young children,  
174 which may be partially due to difficulty in identifying participants with hesitant views [15].

175 In 2011, Opel and colleagues developed the Parent Attitudes about Childhood Vaccines  
176 (PACV) survey, as a tool to assess parental vaccine hesitancy [16]. This has been validated to  
177 identify vaccine hesitance, and predict non-vaccination [17,18]. The PACV has since been  
178 adapted for use in other populations [19–21], translated into multiple languages [22,23] and  
179 used as an outcome in experimental studies [24,25].

180

181 Vaccine hesitancy is context-specific, varying across regions and healthcare systems,  
182 however the PACV has yet to be evaluated in a Western European setting. Our aim was to  
183 administer the PACV to assess vaccine hesitancy and its relationship with non-vaccination  
184 among parents and caregivers of children attending outpatient clinics in an Irish paediatric  
185 hospital. We sought to quantify the rates of vaccine hesitancy and non-vaccination, to  
186 investigate vaccination-related concerns, and to assess and optimise the performance of the  
187 PACV to predict non-vaccination in our population.

188

189



190 **Methods**

191 **Study design, setting, and participants**

192

193 This is a cross-sectional study, reported in line with the Strengthening Reporting of  
194 Observational Studies in Epidemiology (STROBE) statement. It was conducted from  
195 September to December 2018 in the general paediatric outpatients department of  
196 Children’s Health Ireland at Temple Street, Dublin, Ireland, a national acute hospital with  
197 providing secondary and tertiary care to children. General paediatric referrals are drawn  
198 from the north Dublin catchment area, with referrals largely drawn from general  
199 practitioners, subspecialist paediatricians and paediatric surgeons. Parents and caregivers  
200 accompanying a child to a clinic visit were eligible for participation in the study. All parents  
201 and caregivers were approached when checking in for their clinic visit and invited to read a  
202 participant information leaflet about the study and to complete the questionnaire, if  
203 interested. One response per child was invited, so if a child was accompanied by two adults,  
204 only one was invited to participate. The questionnaire was completed in the waiting room  
205 without assistance unless requested. Exclusion criteria included (i) parent/caregiver under  
206 18 years of age, (ii) attending clinic with an interpreter, or (iii) had previously participated.  
207 Completed questionnaires were returned to a closed box, and were not seen by the  
208 attending clinician. This study was approved by the Children’s Health Ireland at Temple  
209 Street Ethics Research Committee (Reference: 18.071).

210

211 **Variables**

212

213 The study tool (included in the supplementary materials) was a questionnaire consisting of  
214 the 15-item PACV questionnaire, demographic questions, vaccination status/intention for  
215 the participant's oldest child, and white-space questions about vaccine-specific and side-  
216 effect concerns. The draft questionnaire was adapted for an Irish population following a  
217 pilot among a convenience sample of five parents/caregivers who met the inclusion criteria.  
218 Sociodemographic questions about income level and marital status were removed as these  
219 were felt to be overly intrusive by our pilot group and would likely have impacted on levels  
220 of participation. The word 'shot' was replaced with 'vaccine' throughout to match Irish  
221 vernacular.

222

223 The PACV is a 15-item questionnaire, divided into 3 domains, behaviour (2 items), safety  
224 and efficacy (4 items) and general attitudes and trust (9 items). There are three response  
225 designs in the PACV; dichotomous, a 5-point Likert scale, and an 11-point scale (e.g. ranging  
226 from '0 – Not sure at all' to '10 – completely sure'). All items are assigned a numeric score.  
227 A simple linear transformation was used to convert raw score to a 0-100 scale, with higher  
228 scores indicating increased hesitance. Participants were dichotomised as 'non-hesitant'  
229 with a score <50, and 'hesitant' if score was  $\geq 50$ , in line with previous research [16] Scores  
230 were also calculated for each domain using a similar linear transformation.

231

232 The vaccination status of the participant's oldest child was collected by self-report (with  
233 response options being received all vaccines, will receive all vaccines, will/has not received  
234 any vaccines or will/has not received certain vaccines). Participants were invited to disclose  
235 specific vaccines and specific side effects they had concern about. Participants' age, level of  
236 educational attainment, and relationship to the child attending, and age of the participant's

237 oldest child were also collected. Education was defined as primary (i.e. up to approximately  
238 8 years), partial or completed secondary (between 9 and 14 years), and tertiary (greater  
239 than 14 years). Relationship to child was defined as mother, father, grandparent, sibling or  
240 other.

241

242

### 243 **Statistical analysis**

244 Statistical analysis was performed using Stata v14.0.with significance set at  $P$ -value  $< 0.05$ .

245 Parametric tests were performed where the data were normally distributed, and non-

246 parametric tests were employed if the data was not normally distributed. We summarised

247 individual PACV item responses, domain scores, and total PACV score, and compared total

248 score between vaccinators and non-vaccinators using a t-test with unequal variance.

249 Univariate and multivariate linear regression were used to assess the association between

250 participant characteristics (age of the participant, their relationship to the child, their

251 educational attainment, age of their oldest child and whether vaccine/side effect concerns

252 were report) and PACV score, estimating beta-coefficients with 95% confidence intervals

253 (CIs). The ability of the PACV to predict non-vaccination was assessed. The area under the

254 Receiver Operator Characteristic (ROC) curve was calculated, representing the accuracy with

255 which the PACV score distinguished between non-vaccinators and vaccinators. This ranges

256 from 0.5 (no better than chance) to 1.0 (perfect accuracy). We identified an optimal cut-off

257 point for classifying hesitancy using three approaches: 1) the point nearest the top left

258 corner of the ROC curve (indicating perfect sensitivity and specificity), 2) the point that

259 maximises the product of the sensitivity and specificity, and 3) the point that maximises the

260 sum of the sensitivity and specificity. Measures of diagnostic accuracy (sensitivity,

261 specificity, positive and negative predictive values, and likelihood ratios for positive and  
262 negative results) with 95% CIs were calculated using the conventional cut-off of  $\geq 50$  for the  
263 PACV, and the optimal cut-off point identified.  
264

265 **Results**

266

267 This study included 436 participants (**Table 1**), with a mean age of 38.1 (SD 7.5) years, the  
268 majority of whom were parents (97.3%) and had completed third-level education (65.9%).  
269 Twenty-two participants (5.5%) reported their oldest child either had or would not receive  
270 some or all vaccines. A childhood vaccine that caused concern was reported by 21.6%, most  
271 frequently HPV and MMR (11.5% and 6.7%, respectively). Concerns were reported more  
272 frequently among non-vaccinators (72.7% versus 19.9% among vaccinators). A total of  
273 16.1% parents/caregivers reported a potential vaccine side effect that they were concerned  
274 about, the most common being autism spectrum disorder (ASD) (4.3%), allergy/anaphylaxis  
275 or an unspecified reaction (2.3%) (**Supplementary Figures 1 and 2**).

276

277 The mean PACV score was 26.9 (SD 19.1) and the distribution of scores is shown in **Figure 1**.  
278 The mean score for the Safety and Efficacy domain was 51.7 (SD 31.4), which was  
279 significantly higher than for the General Attitudes and Trust domain (20.0, SD 19.0), which  
280 was significantly higher than the Behaviour (8.7, SD 24.7) domains ( $p < 0.001$  for both, see  
281 **Supplementary Figure 3**). Vaccinators had a significantly lower mean PACV score compared  
282 to non-vaccinators (25.3 vs 53.2,  $p < 0.001$ ). The scoring of individual questions is shown in  
283 **Figure 2**. The question “*How concerned are you that your child might get a serious side*  
284 *effect from a vaccine?*” had the highest proportion of hesitant responses at 51.8%, while “*All*  
285 *things considered, how much do you trust your child’s doctor?*” had the lowest proportion of  
286 hesitant responses at 3.2%.

287

288 Examining factors associated with PACV score (**Table 2**), there was a statistically significant  
289 relationship between participant age and lower score, with each year increase in age  
290 corresponding to a decrease of -0.75 (95% CI -1.12 to -0.38) in PACV score, independent of  
291 other factors. Conversely, each year increase in the age of a participant's oldest child was  
292 associated with an increase of 0.69 (95% CI 0.31 to 1.07). Reporting a childhood vaccine of  
293 concern was associated with an increase of 10.59 (95% CI 5.02 to 16.17), while reporting a  
294 side effect of concern also had a statistically significant relationship with higher score (8.24,  
295 95% CI 1.49 to 14.99).

296

297 The accuracy of the PACV score to identify non-vaccinators was good, with an area under  
298 the ROC curve of 0.827 (**Figure 3**). The optimal cut-off point was identified 41.67, which was  
299 the point closest to the top left corner of the ROC curve and also maximised both the  
300 product and sum of the sensitivity and specificity. This classified 96 (22%) of participants as  
301 hesitant, as opposed to 63 (14.4%) identified using the conventional cut-off point of  $\geq 50$ ,  
302 and measures of diagnostic accuracy for both are shown in **Supplementary Table 1**. The  
303 optimal cut-off point of 41.67 had a sensitivity of 77.3% (95% CI 54.6% to 92.2%) and a  
304 specificity of 81.3% (95% CI 77.1% to 85.1%). The positive predictive value of being classed  
305 as hesitant was 18.9% (95% CI 11.4% to 28.5%) and the negative predictive value of being  
306 classed as non-hesitant was 98.5% (95% CI 96.4% to 99.5%). The likelihood ratio for being  
307 classed as hesitant was 4.1 (95% CI 3.1 to 5.6) and for being classed as non-hesitant was 0.3  
308 (95% CI 0.1 to 0.6).

309

310 **Discussion**

311

312 Our study, one of the largest PACV studies to date, and the first in a Western European  
313 population, studying the accuracy of PACV in predicting vaccine hesitancy in a population of  
314 parents/caregivers attending a general paediatric outpatient. Employing/implementing a  
315 PACV score > 41 is associated with non-vaccination, with higher sensitivity and specificity  
316 that using a PACV score >50.

317

318 Nearly 15% of our population was vaccine-hesitant using the conventional PACV cut-off,  
319 similar to other populations including Quebec, Canada, (15%) and Indonesia (15.9%) [26,27].

320 The prevalence identified in our study is higher than in Iraq (9.9%) and the United Arab  
321 Emirates (12%) [23,28] and lower than Italy (34.7%) and several USA studies (>20%)  
322 [17,21,29]. This places Ireland in the middle of vaccine hesitancy estimates, which concurs  
323 with the 2018 Wellcome Global Monitor Report [30]. This had asked a sample of Irish  
324 people whether vaccines are important to have, and 91% had somewhat or strongly agreed.

325

326 We found that older participants had a lower PACV (a reduction of -0.75 (95%CI -1.12, -0.38  
327 in PACV score associated with each year increase in age) which has been observed  
328 previously [22]. It is has been suggested that the higher levels of hesitance in younger  
329 parents may be due to increased use and the influence of social media in younger cohorts,  
330 which is predominantly anti-vaccination in outlook [15]. We also found that those with  
331 younger children were more likely to be vaccine-hesitant, contrasting with the Malaysian  
332 study which suggested first-time mothers were more vaccine-hesitant [22].

333

334 Our hesitancy rate was three times higher than the non-vaccination rate, suggesting there  
335 may be a significant proportion of parents who are choosing to vaccinate, but still have  
336 significant vaccine concerns. The national trends in vaccination rates in Ireland align with  
337 this finding. Human papilloma virus vaccine uptake was 85.5% in the 2011/2012 school year,  
338 but fell to 51% in 2016/2017, coinciding with a rise in anti-HPV vaccine publicity [31]. This  
339 experience has been mirrored internationally [32]. A concerted, multi-modal cross-sectoral  
340 alliance was built by Ireland's National Immunisation Office to reverse this trend, resulting  
341 in an increase in the vaccination rates to 64.1% in 2017/2018 [33]. This experience  
342 illustrates how hesitant parents may be persuaded for or against vaccination, depending on  
343 the information they are provided with. More than one in ten participants in this study were  
344 still concerned about HPV vaccination today, emphasising the need for continued vigilance  
345 against future declines in vaccination.

346

347 As in the anti-HPV vaccine campaign, our results showed that safety and efficacy is the  
348 primary motivator for vaccine hesitance, with this domain having the highest score, with a  
349 mean of 51.7(31.4). This result mirrors other PACV research worldwide [20,27], and safety  
350 concerns are the most commonly cited barrier to vaccination [34]. Keeping children healthy  
351 is one of the most important considerations for parents, and choices can be based on a  
352 complex balancing of risks and benefits [35]. The fraudulent association between vaccines  
353 and ASD has been thoroughly debunked, however this side effect was the single most  
354 commonly cited in our population (4.3%). Similar to HPV, MMR vaccination rates declined  
355 sharply following this controversy in the late 1990s. In the intervening period, while  
356 immunisation levels have recovered, parental reservations regarding ASD have remained



357 relatively unchanged [36]. Allaying these concerns is important for ensuring continued  
358 improvements in MMR uptake.  
359  
360 Over 90% of our participants trusted their doctor. Trust in healthcare professionals, and  
361 paediatricians in particular, has been consistently described as critical for vaccine uptake  
362 [14]. Indeed, some American surveys of parents of vaccination aged children suggest that  
363 the influence of the paediatrician is the single most powerful factor in vaccine acceptance  
364 [37]. This places professionals in a unique position to promote vaccination amongst their  
365 patient's parents. Increasing numbers of paediatricians are caring for the children of parents  
366 who have refused a vaccine [38], but up to half of these may be convinced to accept  
367 vaccination with continued engagement [39]. It has become the recommendation or  
368 professional associations including the American Academy of Paediatrics to continue to  
369 engage with vaccine-hesitant parents, in the hopes of a positive vaccination decision in the  
370 future [40].  
371  
372 These consultations can be challenging. The provision of information about the safety of  
373 vaccines and the dangers of vaccine preventable diseases, while important, may not alone  
374 be sufficient to reduce hesitancy, change minds and increase vaccine uptake [41].  
375 Communication is based on a mutual understanding that both parents and healthcare  
376 professionals are acting in what they consider to be the best interests of the child [42] It is  
377 crucial to engage with specific concerns raised by parents about specific vaccines for their  
378 child, and recognise that having concerns is a natural, even healthy response [43]. Evidence-  
379 based methods for vaccine promotion amongst parents include using a presumptive, rather  
380 than a participatory, approach to vaccine discussion, to make vaccine acceptance rather

381 than refusal the default position [44]. For those who resist vaccination, motivational  
382 interviewing techniques have been shown to be effective, as has persistence with positive  
383 messaging over the course of the clinical relationship [44].

384

385 In addition, it has become increasingly apparent that the use of personal stories to illustrate  
386 the importance of vaccination and the dangers of vaccine-preventable diseases is an  
387 effective tool [45]. While anecdotes have traditionally been frowned upon by the medical  
388 community, they have played a key role in combatting the proliferation of first-hand  
389 accounts of perceived harms from vaccination, amplified by social media, that result in  
390 vaccine refusal. Empirical evidence has shown that anti-vaccination narratives can override  
391 the effect of statistical information and influence risk perception about vaccines, particularly  
392 when the narrative is highly emotional [46]. Similar strategies to combat these sentiments  
393 have been employed. For example, stories involving vaccine preventable disease  
394 experiences, uneventful vaccinations, or ‘conversions’ of previously anti-vaccination voices  
395 have all been used to effect in campaigns internationally [45]. Directing parents to pro-  
396 vaccination parent curated social media platforms may counter the anti-vaccination  
397 equivalents.

398

399 Applying these techniques in clinical practice can be time-consuming and daunting, which  
400 can have negative outcomes for both parents and healthcare professionals [47]. As such,  
401 targeting the interventions to where they are most needed is critical. Our results suggest  
402 the PACV is a robust, accurate tool to identify parents who are vaccine hesitant, as a focus  
403 for targeted vaccine promotion. We identified a novel cut-off point for hesitance to optimise  
404 the tool’s performance in detecting potential non-vaccinators. Ours is lower than the

405 conventional cut-off point (41.7 versus 50), identifying 22% rather than 14.4% of our  
406 population as hesitant, optimising sensitivity and specificity. Using the PACV with our new  
407 cut-off point to target non-vaccinators, rather than an untargeted approach, we increase  
408 the likelihood of targeting a non-vaccinator from 1 in 20, to 1 in 5, assuming a non-  
409 vaccination rate of 5%, as in our population. In clinical practice, the PACV offers the realistic  
410 prospect of engaging parents who are at high risk of non-vaccination, in a timely fashion.  
411 Based on the negative predictive value, those identified as non-hesitant have a high  
412 probability (98.5%) of being vaccinators and therefore a clinician is unlikely to miss a non-  
413 vaccinator. In more time-constrained settings, the higher conventional cut-off point of 50  
414 could be used. This would increase the specificity, classifying fewer people as hesitant with a  
415 higher proportion of these being non-vaccinators, but at the expense of lower sensitivity,  
416 resulting in more non-vaccinators being classified as non-hesitant.

417

418 Our study was limited by lack of access to vaccination data and relied on the use of self-  
419 reported vaccination, as have many previous vaccine hesitancy studies [4,22,23,27].  
420 Reliability of self-report has only been evaluated in adults and for specified vaccinations  
421 [48,49], However parental report of adherence to childhood vaccination in general may be  
422 expected to be more accurate, especially for deliberate partial or complete non-vaccination.  
423 In the absence of national life-long registries however, self-report remains the practical  
424 option for vaccination information. We used vaccination status of the oldest child in our  
425 study, with a mean age of 9.9. This is older than many other PACV studies, and may affect  
426 recall. However with the HPV vaccine as a further vaccination choice that parents of these  
427 older children will still have to make, evaluating vaccine hesitancy in this group is vital. In  
428 fact, hesitancy in this group may be particularly important, given the anti-vaccination

429 movement has focused largely on HPV vaccines. Secondly, our population were attending a  
430 paediatric clinic, and therefore may not be representative of a general population of  
431 children. For instance, there is evidence that children with chronic conditions, more  
432 prevalent in a hospital attending population than the community at large, may be under-  
433 vaccinated when compared with their peers [50]. Our results should not be assumed to  
434 apply to children attending other settings, including primary care or routine childhood  
435 screening for development or growth. However the findings are informative for clinicians  
436 who are encountering a population similar to that in this study. Our non-vaccination rates  
437 are lower than national and local averages [6,33], which may reflect this as well as social  
438 desirability bias. The representativeness of our population (e.g. 79.1% being mothers) may  
439 limit the generalisability of our results to others involved in vaccination decisions. That said,  
440 there are indications that mothers are the predominant decision makers in terms of their  
441 children's health [51]

442

#### 443 **Conclusion**

444

445 In conclusion, we found that vaccine hesitancy was relatively common in our population,  
446 and that the PACV identified non-vaccination with high accuracy. Using a lower cut-off point  
447 of >41.7 may optimise use of the PACV compared to the conventionally used cut-off point of  
448 50. Therefore, the PACV may be a useful tool for paediatricians to effectively screen their  
449 clinic for vaccine hesitant-parents and to support vaccination uptake over the course of  
450 childhood.

451

452 **References**

- 453 1 Plotkin SL, Plotkin SA. A short history of vaccination. In: *Vaccines: Sixth Edition*.  
454 2012. doi:10.1016/B978-1-4557-0090-5.00017-3
- 455 2 Vanderslott S, Dadonaite B. Vaccination. OurWorldInData.org.  
456 2013.<https://ourworldindata.org/vaccination> (accessed 29 Jun 2020).
- 457 3 Zhou F, Shefer A, Wenger J, *et al*. Economic evaluation of the routine childhood  
458 immunization program in the united states, 2009. *Pediatrics* Published Online First:  
459 2014. doi:10.1542/peds.2013-0698
- 460 4 Drolet M, Bénard É, Pérez N, *et al*. Population-level impact and herd effects following  
461 the introduction of human papillomavirus vaccination programmes: updated  
462 systematic review and meta-analysis. *Lancet* Published Online First: 2019.  
463 doi:10.1016/S0140-6736(19)30298-3
- 464 5 Iacobucci G. Child vaccination rates in England fall across the board, figures show.  
465 *BMJ*. 2019. doi:10.1136/bmj.l5773
- 466 6 (HPSC) H-HPSC. Summary Immunisation Uptake Statistics Data up to Q3 2019.  
467 2020.
- 468 7 Barrett P, Cotter S, Ryan F, *et al*. A national measles outbreak in Ireland linked to a  
469 single imported case, April to September, 2016. *Eurosurveillance* Published Online  
470 First: 2018. doi:10.2807/1560-7917.ES.2018.23.31.1700655
- 471 8 Ferenczi A, Gee S, Cotter S, *et al*. Ongoing mumps outbreak among adolescents and  
472 young adults, Ireland, August 2018 to January 2020. *Eurosurveillance* Published  
473 Online First: 2020. doi:10.2807/1560-7917.ES.2020.25.4.2000047
- 474 9 Lo NC, Hotez PJ. Public health and economic consequences of vaccine hesitancy for  
475 measles in the United States. *JAMA Pediatr* Published Online First: 2017.  
476 doi:10.1001/jamapediatrics.2017.1695
- 477 10 Organisation WH. Ten threats to global health in 2019.  
478 <https://www.who.int/emergencies/ten-threats-to-global-health-in-2019>.
- 479 11 The World Health Organization. Report of the Sage Working Group on Vaccine  
480 Hesitancy. 2014.
- 481 12 Luthy KE, Beckstrand RL, Peterson NE. Parental Hesitation as a Factor in Delayed  
482 Childhood Immunization. *J Pediatr Heal Care* Published Online First: 2009.  
483 doi:10.1016/j.pedhc.2008.09.006
- 484 13 Gowda C, Schaffer SE, Kopec K, *et al*. Does the relative importance of MMR vaccine  
485 concerns differ by degree of parental vaccine hesitancy? An exploratory study. *Hum*  
486 *Vaccines Immunother* Published Online First: 2013. doi:10.4161/hv.22065
- 487 14 Benin AL, Wisler-Scher DJ, Colson E, *et al*. Qualitative analysis of mothers' decision-

- 488 making about vaccines for infants: The importance of trust. *Pediatrics* Published  
489 Online First: 2006. doi:10.1542/peds.2005-1728
- 490 15 Smith LE, Amlôt R, Weinman J, *et al.* A systematic review of factors affecting  
491 vaccine uptake in young children. *Vaccine*. 2017. doi:10.1016/j.vaccine.2017.09.046
- 492 16 Opel DJ, Mangione-Smith R, Taylor JA, *et al.* Development of a survey to identify  
493 vaccine-hesitant parents: The parent attitudes about childhood vaccines survey. *Hum*  
494 *Vaccin* Published Online First: 2011. doi:10.4161/hv.7.4.14120
- 495 17 Opel DJ, Taylor JA, Mangione-Smith R, *et al.* Validity and reliability of a survey to  
496 identify vaccine-hesitant parents. *Vaccine* Published Online First: 2011.  
497 doi:10.1016/j.vaccine.2011.06.115
- 498 18 Opel DJ, Taylor JA, Zhou C, *et al.* The relationship between parent attitudes about  
499 childhood vaccines survey scores and future child immunization status: A validation  
500 study. *JAMA Pediatr* Published Online First: 2013.  
501 doi:10.1001/jamapediatrics.2013.2483
- 502 19 Langkamp DL, Dusseau A, Brown MF. Vaccine Hesitancy and Low Immunization  
503 Rates in Children with Down Syndrome. *J Pediatr* Published Online First: 2020.  
504 doi:10.1016/j.jpeds.2020.03.025
- 505 20 Roberts JR, Thompson D, Rogacki B, *et al.* Vaccine hesitancy among parents of  
506 adolescents and its association with vaccine uptake. *Vaccine* Published Online First:  
507 2015. doi:10.1016/j.vaccine.2015.01.068
- 508 21 Strelitz B, Gritton J, Klein EJ, *et al.* Parental vaccine hesitancy and acceptance of  
509 seasonal influenza vaccine in the pediatric emergency department. *Vaccine* Published  
510 Online First: 2015. doi:10.1016/j.vaccine.2015.02.034
- 511 22 Mohd Azizi FS, Kew Y, Moy FM. Vaccine hesitancy among parents in a multi-ethnic  
512 country, Malaysia. *Vaccine* Published Online First: 2017.  
513 doi:10.1016/j.vaccine.2017.04.010
- 514 23 Alsuwaidi AR, Elbarazi I, Al-Hamad S, *et al.* Vaccine hesitancy and its determinants  
515 among Arab parents: a cross-sectional survey in the United Arab Emirates. *Hum*  
516 *Vaccines Immunother* Published Online First: 2020.  
517 doi:10.1080/21645515.2020.1753439
- 518 24 Opel DJ, Henrikson N, Lepere K, *et al.* Previsit screening for parental vaccine  
519 hesitancy: A cluster randomized trial. *Pediatrics* Published Online First: 2019.  
520 doi:10.1542/peds.2019-0802
- 521 25 Williams SE, Rothman RL, Offit PA, *et al.* A randomized trial to increase acceptance  
522 of childhood vaccines by vaccine-hesitant parents: A pilot study. *Acad Pediatr*  
523 Published Online First: 2013. doi:10.1016/j.acap.2013.03.011
- 524 26 Dubé È, Farrands A, Lemaitre T, *et al.* Overview of knowledge, attitudes, beliefs,

- 525 vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec,  
526 Canada. *Hum Vaccines Immunother* Published Online First: 2019.  
527 doi:10.1080/21645515.2018.1509647
- 528 27 Yufika A, Wagner AL, Nawawi Y, *et al.* Parents' hesitancy towards vaccination in  
529 Indonesia: A cross-sectional study in Indonesia. *Vaccine* Published Online First: 2020.  
530 doi:10.1016/j.vaccine.2020.01.072
- 531 28 Raof AM. Parental Attitude and Beliefs towards Child Vaccination: Identifying  
532 Vaccine Hesitant Groups in a Family Health Center, Erbil City, Iraq. *World Fam Med*  
533 *Journal/Middle East J Fam Med* Published Online First: 2018.  
534 doi:10.5742/mewfm.2018.93386
- 535 29 Bianco A, Mascaro V, Zucco R, *et al.* Parent perspectives on childhood vaccination:  
536 How to deal with vaccine hesitancy and refusal? *Vaccine* Published Online First: 2019.  
537 doi:10.1016/j.vaccine.2018.12.062
- 538 30 Migone C, Barrett T, Cotter S, *et al.* The uptake of human papillomavirus vaccine in  
539 Irish schools: The impact of disadvantage. *Ir Med J* 2017.
- 540 31 Suppli CH, Hansen ND, Rasmussen M, *et al.* Decline in HPV-vaccination uptake in  
541 Denmark - The association between HPV-related media coverage and HPV-  
542 vaccination. *BMC Public Health* Published Online First: 2018. doi:10.1186/s12889-  
543 018-6268-x
- 544 32 (HPSC) H-HPSC. HPV, MenC booster and Tdap vaccine uptake in Ireland,  
545 2017/2018. 2019.
- 546 33 Williams SE. What are the factors that contribute to parental vaccine-hesitancy and  
547 what can we do about it? *Hum Vaccines Immunother* Published Online First: 2014.  
548 doi:10.4161/hv.28596
- 549 34 Henwood K, Pidgeon N, Sarre S, *et al.* Risk, framing and everyday life:  
550 Epistemological and methodological reflections from three socio-cultural projects.  
551 *Heal Risk Soc* Published Online First: 2008. doi:10.1080/13698570802381451
- 552 35 Allan N, Harden J. Parental decision-making in uptake of the MMR vaccination: A  
553 systematic review of qualitative literature. *J. Public Heal. (United Kingdom)*. 2015.  
554 doi:10.1093/pubmed/fdu075
- 555 36 Taylor JA, Darden PM, Slora E, *et al.* The influence of provider behavior, parental  
556 characteristics, and a public policy initiative on the immunization status of children  
557 followed by private pediatricians: A study from pediatric research in office settings.  
558 *Pediatrics* 1997.
- 559 37 Hough-Telford C, Kimberlin DW, Aban I, *et al.* Vaccine delays, refusals, and patient  
560 dismissals: A survey of pediatricians. *Pediatrics*. 2016. doi:10.1542/peds.2016-2127
- 561 38 Opel DJ, Heritage J, Taylor JA, *et al.* The Architecture of provider-Parent vaccine

- 562 discussions at health supervision visits. *Pediatrics* Published Online First: 2013.  
563 doi:10.1542/peds.2013-2037
- 564 39 Diekema DS. Responding to parental refusals of immunization of children. *Pediatrics*  
565 Published Online First: 2005. doi:10.1542/peds.2005-0316
- 566 40 Nyhan B, Reifler J, Richey S, *et al.* Effective messages in vaccine promotion: A  
567 randomized trial. *Pediatrics* Published Online First: 2014. doi:10.1542/peds.2013-  
568 2365
- 569 41 Healy CM, Pickering LK. How to communicate with vaccine-hesitant parents.  
570 *Pediatrics*. 2011. doi:10.1542/peds.2010-1722S
- 571 42 Bedford HE, Elliman DAC. Fifteen-minute consultation: Vaccine-hesitant parents.  
572 *Arch Dis Child Educ Pract Ed* Published Online First: 2019. doi:10.1136/archdischild-  
573 2019-316927
- 574 43 Williams JTB, O'Leary ST, Nussbaum AM. Caring for the Vaccine Hesitant Family:  
575 Evidence-Based Alternatives to Dismissal. *J Pediatr* Published Online First: 2020.  
576 doi:10.1016/j.jpeds.2020.05.029
- 577 44 Shelby A, Ernst K. Story and science: How providers and parents can utilize  
578 storytelling to combat anti-vaccine misinformation. *Hum. Vaccines Immunother.*  
579 2013. doi:10.4161/hv.24828
- 580 45 Betsch C, Ulshöfer C, Renkewitz F, *et al.* The influence of narrative v. statistical  
581 information on perceiving vaccination risks. *Med Decis Mak* Published Online First:  
582 2011. doi:10.1177/0272989X11400419
- 583 46 Kempe A, Daley MF, McCauley MM, *et al.* Prevalence of parental concerns about  
584 childhood vaccines: The experience of primary care physicians. *Am J Prev Med*  
585 Published Online First: 2011. doi:10.1016/j.amepre.2010.12.025
- 586 47 Loulergue P, Pulcini C, Massin S, *et al.* Validity of self-reported vaccination status  
587 among French healthcare students. *Clin Microbiol Infect* Published Online First: 2014.  
588 doi:10.1111/1469-0691.12759
- 589 48 Cossio MLT, Giesen LF, Araya G, *et al.* No Title No Title. *Instrumentos Fam*  
590 2012;XXXIII:81–7. doi:10.1007/s13398-014-0173-7.2
- 591 49 Hofstetter AM, Camargo S, Natarajan K, *et al.* Vaccination Coverage of Adolescents  
592 With Chronic Medical Conditions. *Am J Prev Med* Published Online First: 2017.  
593 doi:10.1016/j.amepre.2017.07.017
- 594 50 Ranji U, Salganicoff A. Balancing on Shaky Ground: Women, Work, and Family  
595 Health. 2014.

596

597



598 **Tables**

599

600 Table 1. Descriptive characteristics of participants

<b>Characteristic</b>	<b>Total (n=436)</b>	<b>Vaccinated (n=391)</b>	<b>Non-vaccinated (n=22)</b>
<b>Age of participant (years), Mean (SD)</b>	38.1 (7.53)	38.4 (7.38)	37.0 (8.80)
<b>Relationship, n (%)</b>			
Mother	344 (79.1)	307 (78.5)	19 (86.4)
Father	79 (18.2)	73 (18.7)	3 (13.6)
Other	11 (1.4)	11 (2.8)	0 (0.0)
<b>Educational attainment, n (%)</b>			
Primary	20 (4.7)	19 (4.9)	0 (0.0)
Some secondary	34 (8.0)	30 (7.8)	2 (9.5)
All secondary	91 (21.4)	82 (21.2)	4 (19.0)
Tertiary	280 (65.9)	255 (66.1)	15 (71.4)
<b>Age of oldest child (years), Mean (SD)</b>	9.9 (7.01)	10.0 (6.94)	9.9 (7.32)
<b>Concerned by at least one childhood vaccine, n (%)</b>	94 (21.6)	78 (19.9)	16 (72.7)
<b>Reported a side effect of concern, n (%)</b>	59 (13.5)	44 (11.3)	13 (59.1)
<b>Reported vaccination status of oldest child, n (%)</b>			
Received all vaccinations	348 (84.3)	348 (89.0)	
Intend to fully vaccinate	43 (10.4)	43 (11.0)	
Not received any vaccines	3 (0.7)		3 (13.4)
Not receiving certain vaccines	19 (4.6)		19 (86.6)

601

602 Table 2. Association of participant factors with PACV score from univariate (unadjusted) and  
603 multivariate (adjusted) linear regression

	<b>Unadjusted</b>		<b>Adjusted</b>	
	<b>Beta coefficient (95% CI)</b>	<b>p value</b>	<b>Beta coefficient (95% CI)</b>	<b>p value</b>
<b>Age of participant, years</b>	-0.16 (-0.42, 0.09)	0.207	-0.75 (-1.12, -0.38)	<0.001
<b>Relationship</b>				
Mother (reference group)	0.00		0.00	
Father	-3.51 (-8.19, 1.18)	0.142	1.45 (-4.26, 7.16)	0.618
Other	4.23 (-6.79, 15.26)	0.451	9.04 (-10.52, 28.60)	0.364
<b>Educational attainment</b>				
Primary	5.29 (-3.50, 14.07)	0.238	6.42 (-4.87, 17.72)	0.264
Some secondary	1.36 (-5.53, 8.26)	0.697	5.07 (-4.71, 14.86)	0.308
All secondary	0.47 (-4.11, 5.05)	0.841	-0.06 (-5.85, 5.74)	0.984
Third level (reference group)	0.00		0.00	
<b>Age of oldest child, years</b>	0.32 (0.02, 0.63)	0.039	0.69 (0.31, 1.07)	<0.001
<b>Concerned by at least one childhood vaccine</b>	11.29 (7.04, 15.53)	<0.001	10.59 (5.02, 16.17)	<0.001
<b>Reported a side-effect of concern</b>	11.98 (6.84, 17.12)	<0.001	8.24 (1.49, 14.99)	0.017

604

605 **Figures**

606

607 Figure 1. Distribution of PACV scores

608


609 Figure 2. Distribution of responses for each of the 15 items within the PACV


610

611 Figure 3. Receiver Operating Characteristic (ROC) curve for the PACV score in predicting  
612 non-vaccination


### **Declaration of interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.





■ Non-hesitant ■ Unsure ■ Hesitant



Area under ROC curve = 0.8271